{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:58:27Z","timestamp":1780808307189,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T00:00:00Z","timestamp":1775952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100012957","name":"Friedrich-Schiller-Universit\u00e4t Jena","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012957","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Complete macroscopic tumor resection is the strongest prognostic factor in advanced epithelial tubo-ovarian and primary peritoneal cancer, yet benefit from maximum-effort cytoreductive surgery may vary with tumor distribution and site-specific resections. We aimed to identify predictors of long-term survival, considering postoperative morbidity, to inform preoperative stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods<\/jats:title>\n                    <jats:p>This study had a retrospective single-center cohort of 302 all-comers patients with International Federation of Gynecology and Obstetrics\/American Joint Committee on Cancer (FIGO\/AJCC) IIIC\u2013IV epithelial tubo-ovarian or primary peritoneal cancer undergoing maximum-effort cytoreductive surgery in a European Society of Gynecological Oncology (ESGO)-certified high-volume tertiary referral center (2006\u20132021). Major complications (Clavien\u2013Dindo \u2265 IIIb) were analyzed using multivariable logistic regression; progression-free and overall survival (PFS\/OS) using Cox regression. Subgroup analyses explored site-specific bowel resections.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Complete resection was achieved in 259 (85.8%) patients, requiring high surgical complexity in 221 (73.2%, Surgical Complexity Score \u2265 8). Intestinal segment resections were performed in 71.5% of patients, including ileocecal resection in 24.5%. Large bowel resection (OR 2.708,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.002) significantly increased major postoperative morbidity. Anastomotic leakage occurred in 6.0%, independent of transitory stoma formation (\n                      <jats:italic>p<\/jats:italic>\n                      = 0.759). Small bowel resection independently predicted impaired long-term survival (3-year OS 31.8% versus 57.0%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Ileocecal resections were associated with poorest outcome (3-year OS 24.2%,\n                      <jats:italic>p<\/jats:italic>\n                      &lt; 0.001). Complete macroscopic resection remained prognostically beneficial. Neoadjuvant chemotherapy (13.9%) and high surgical complexity did not negatively affect long-term survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Ileocecal and small bowel involvement are independently associated with inferior survival despite complete cytoreduction in FIGO IIIC\u2013IV disease. These findings support preoperative triage and counseling by the multidisciplinary tumor board, with selective consideration of primary systemic therapy with planned interval cytoreduction for extensive small bowel\/ileocecal disease, particularly in frail or complex patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1245\/s10434-026-19485-5","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T19:13:04Z","timestamp":1776021184000},"page":"6639-6651","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Ileocecal and Small Bowel Involvement Are Independently Associated with Inferior Survival Despite Complete Cytoreduction in FIGO IIIC\u2013IV Tubo-Ovarian and Primary Peritoneal Carcinoma"],"prefix":"10.1245","volume":"33","author":[{"given":"Ingo B.","family":"Runnebaum","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara Evangelia","family":"Goerdt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyen Thi Thanh","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davit","family":"Bokhua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,12]]},"reference":[{"issue":"10290","key":"19485_CR1","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.1016\/S0140-6736(21)00731-5","volume":"397","author":"U Menon","year":"2021","unstructured":"Menon U, Gentry-Maharaj A, Burnell M, et al. Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021;397(10290):2182\u201393. https:\/\/doi.org\/10.1016\/S0140-6736(21)00731-5.","journal-title":"Lancet."},{"issue":"12","key":"19485_CR2","doi-asserted-by":"publisher","first-page":"10179","DOI":"10.3390\/curroncol30120741","volume":"30","author":"R Sowamber","year":"2023","unstructured":"Sowamber R, Lukey A, Huntsman D, Hanley G. Ovarian cancer: from precursor lesion identification to population-based prevention programs. Curr Oncol. 2023;30(12):10179\u201394. https:\/\/doi.org\/10.3390\/curroncol30120741.","journal-title":"Curr Oncol."},{"issue":"1","key":"19485_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1004514","volume":"22","author":"A Kather","year":"2025","unstructured":"Kather A, Arefian H, Schneider C, Hartmann M, Runnebaum IB. Ovarian cancer prevention through opportunistic salpingectomy during abdominal surgeries: a cost-effectiveness modeling study. PLoS Med. 2025;22(1):e1004514. https:\/\/doi.org\/10.1371\/journal.pmed.1004514.","journal-title":"PLoS Med."},{"issue":"5","key":"19485_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/bjs.11419","volume":"107","author":"G Tomasch","year":"2020","unstructured":"Tomasch G, Lemmerer M, Oswald S, et al. Prophylactic salpingectomy for prevention of ovarian cancer at the time of elective laparoscopic cholecystectomy. Br J Surg. 2020;107(5):519\u201324. https:\/\/doi.org\/10.1002\/bjs.11419.","journal-title":"Br J Surg."},{"issue":"9","key":"19485_CR5","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1093\/bjs\/znad203","volume":"110","author":"AM Cathcart","year":"2023","unstructured":"Cathcart AM, Harrison R, Luccarelli J. Opportunistic salpingectomy during non-gynaecological surgery in the United States: a population-based retrospective study. Br J Surg. 2023;110(9):1215\u20137. https:\/\/doi.org\/10.1093\/bjs\/znad203.","journal-title":"Br J Surg."},{"issue":"6","key":"19485_CR6","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1002\/cncr.24149","volume":"115","author":"A Du Bois","year":"2009","unstructured":"Du Bois A, Reuss A, Pujade-Lauraine E, Harter P, Ray-Coquard I, Pfisterer J. Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux Pour les Etudes des Cancers de l\u2019Ovaire (GINECO). Cancer. 2009;115(6):1234\u201344. https:\/\/doi.org\/10.1002\/cncr.24149.","journal-title":"Cancer."},{"issue":"3","key":"19485_CR7","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.ygyno.2013.05.040","volume":"130","author":"S-J Chang","year":"2013","unstructured":"Chang S-J, Hodeib M, Chang J, Bristow RE. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis. Gynecol Oncol. 2013;130(3):493\u20138. https:\/\/doi.org\/10.1016\/j.ygyno.2013.05.040.","journal-title":"Gynecol Oncol."},{"issue":"8","key":"19485_CR8","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1200\/JCO.2014.56.3106","volume":"33","author":"NS Horowitz","year":"2015","unstructured":"Horowitz NS, Miller A, Rungruang B, et al. Does aggressive surgery improve outcomes? Interaction between preoperative disease burden and complex surgery in patients with advanced-stage ovarian cancer: an analysis of GOG 182. J Clin Oncol. 2015;33(8):937\u201343. https:\/\/doi.org\/10.1200\/JCO.2014.56.3106.","journal-title":"J Clin Oncol."},{"issue":"11","key":"19485_CR9","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1245\/s10434-021-10490-4","volume":"28","author":"DJ Brennan","year":"2021","unstructured":"Brennan DJ, Moran BJ. Time to evolve terminology from \u201cdebulking\u201d to cytoreductive surgery (CRS) in ovarian cancer. Ann Surg Oncol. 2021;28(11):5805\u20137. https:\/\/doi.org\/10.1245\/s10434-021-10490-4.","journal-title":"Ann Surg Oncol."},{"key":"19485_CR10","unstructured":"Hrsg.: Leitlinienprogramm Onkologie. S3-Leitlinie Maligne Ovarialtumoren. 2022."},{"issue":"6","key":"19485_CR11","doi-asserted-by":"publisher","first-page":"676.e1","DOI":"10.1016\/j.ajog.2007.10.495","volume":"197","author":"GD Aletti","year":"2007","unstructured":"Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1-7. https:\/\/doi.org\/10.1016\/j.ajog.2007.10.495.","journal-title":"Am J Obstet Gynecol."},{"issue":"10","key":"19485_CR12","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1056\/NEJMoa0908806","volume":"363","author":"I Vergote","year":"2010","unstructured":"Vergote I, Trop\u00e9 CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363(10):943\u201353. https:\/\/doi.org\/10.1056\/NEJMoa0908806.","journal-title":"N Engl J Med."},{"issue":"9990","key":"19485_CR13","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/S0140-6736(14)62223-6","volume":"386","author":"S Kehoe","year":"2015","unstructured":"Kehoe S, Hook J, Nankivell M, et al. Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial. Lancet. 2015;386(9990):249\u201357. https:\/\/doi.org\/10.1016\/S0140-6736(14)62223-6.","journal-title":"Lancet."},{"key":"19485_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.ejca.2016.05.017","volume":"64","author":"T Onda","year":"2016","unstructured":"Onda T, Satoh T, Saito T, et al. Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III\/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. Eur J Cancer. 2016;64:22\u201331. https:\/\/doi.org\/10.1016\/j.ejca.2016.05.017.","journal-title":"Eur J Cancer."},{"issue":"11","key":"19485_CR15","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1136\/ijgc-2020-001640","volume":"30","author":"A Fagotti","year":"2020","unstructured":"Fagotti A, Ferrandina MG, Vizzielli G, et al. Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. 2020;30(11):1657\u201364. https:\/\/doi.org\/10.1136\/ijgc-2020-001640.","journal-title":"Int J Gynecol Cancer."},{"issue":"7","key":"19485_CR16","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1097\/IGC.0000000000000767","volume":"26","author":"D Querleu","year":"2016","unstructured":"Querleu D, Planchamp F, Chiva L, et al. European Society of Gynaecologic Oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer. 2016;26(7):1354\u201363. https:\/\/doi.org\/10.1097\/IGC.0000000000000767.","journal-title":"Int J Gynecol Cancer."},{"issue":"4","key":"19485_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/ijgc-2020-001248","volume":"30","author":"C Fotopoulou","year":"2020","unstructured":"Fotopoulou C, Concin N, Planchamp F, et al. Quality indicators for advanced ovarian cancer surgery from the European Society of Gynaecological Oncology (ESGO): 2020 update. Int J Gynecol Cancer. 2020;30(4):436\u201340. https:\/\/doi.org\/10.1136\/ijgc-2020-001248.","journal-title":"Int J Gynecol Cancer."},{"key":"19485_CR18","doi-asserted-by":"publisher","unstructured":"Rashid R, Sohrabi C, Kerwan A, et al. The STROCSS 2024 guideline: strengthening the reporting of cohort cross-sectional and case\u2013control studies in surgery. Int J Surg. 2024;110(6):3151\u201365. https:\/\/doi.org\/10.1097\/JS9.0000000000001268","DOI":"10.1097\/JS9.0000000000001268"},{"key":"19485_CR19","doi-asserted-by":"publisher","unstructured":"Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. PLOS Med. 2015;12(10):e1001885. https:\/\/doi.org\/10.1371\/journal.pmed.1001885","DOI":"10.1371\/journal.pmed.1001885"},{"issue":"9","key":"19485_CR20","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1245\/s10434-024-15643-9","volume":"31","author":"M-S Kim","year":"2024","unstructured":"Kim M-S, Lee AJ, Shim S-H, et al. Comparison of outcomes in bowel resections by gynecologic oncologists versus general surgeons during maximal cytoreductive surgery for advanced ovarian cancer: Gynecologic Oncology Research Investigators Collaboration study (GORILLA-3006). Ann Surg Oncol. 2024;31(9):6040\u20137. https:\/\/doi.org\/10.1245\/s10434-024-15643-9.","journal-title":"Ann Surg Oncol."},{"key":"19485_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/978-1-4613-1247-5_23","volume":"82","author":"P Jacquet","year":"1996","unstructured":"Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359\u201374. https:\/\/doi.org\/10.1007\/978-1-4613-1247-5_23.","journal-title":"Cancer Treat Res."},{"issue":"4","key":"19485_CR22","doi-asserted-by":"publisher","first-page":"983","DOI":"10.7150\/jca.32317","volume":"11","author":"M Zhou","year":"2020","unstructured":"Zhou M, Wang D, Long Z, Zhang Y, Liu J. Role of laparotomy-based parameters in assessment of optimal primary debulking surgery and long-term outcomes in patients with stage IIIC epithelial ovarian cancer. J Cancer. 2020;11(4):983\u20139. https:\/\/doi.org\/10.7150\/jca.32317.","journal-title":"J Cancer."},{"key":"19485_CR23","doi-asserted-by":"publisher","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications. Ann Surg. 2004;240(2):205\u201313. https:\/\/doi.org\/10.1097\/01.sla.0000133083.54934.ae","DOI":"10.1097\/01.sla.0000133083.54934.ae"},{"key":"19485_CR24","doi-asserted-by":"publisher","unstructured":"Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019;380(9):822\u201332. https:\/\/doi.org\/10.1056\/NEJMoa1808424","DOI":"10.1056\/NEJMoa1808424"},{"key":"19485_CR25","doi-asserted-by":"publisher","DOI":"10.1097\/JS9.0000000000002288","author":"Z Chen","year":"2025","unstructured":"Chen Z, Ouyang H, Sun B, Ding J, Zhang Y, Li X. Utilizing explainable machine learning for progression-free survival prediction in high-grade serous ovarian cancer: insights from a prospective cohort study. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000002288.","journal-title":"Int J Surg."},{"issue":"1","key":"19485_CR26","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s13048-020-00700-0","volume":"13","author":"A Laios","year":"2020","unstructured":"Laios A, Gryparis A, DeJong D, Hutson R, Theophilou G, Leach C. Predicting complete cytoreduction for advanced ovarian cancer patients using nearest-neighbor models. J Ovarian Res. 2020;13(1):117. https:\/\/doi.org\/10.1186\/s13048-020-00700-0.","journal-title":"J Ovarian Res."},{"issue":"1","key":"19485_CR27","doi-asserted-by":"publisher","first-page":"12300","DOI":"10.1038\/s41598-022-16100-x","volume":"12","author":"T Bisgin","year":"2022","unstructured":"Bisgin T, Sokmen S, Manoglu B, Ozkardesler S, Sarioglu S, Ellidokuz H. Neglected prognostic importance of ileal resection in patients with peritoneal metastasis. Sci Rep. 2022;12(1):12300. https:\/\/doi.org\/10.1038\/s41598-022-16100-x.","journal-title":"Sci Rep."},{"issue":"9","key":"19485_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419\u201325. https:\/\/doi.org\/10.1200\/JCO.2008.19.1684.","journal-title":"J Clin Oncol."},{"issue":"6","key":"19485_CR29","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1002\/bjs.6135","volume":"95","author":"S-W Lim","year":"2008","unstructured":"Lim S-W, Lim S-B, Park J-Y, Park S-Y, Choi HS, Jeong S-Y. Outcomes of colorectal anastomoses during pelvic exenteration for gynaecological malignancy. Br J Surg. 2008;95(6):770\u20133. https:\/\/doi.org\/10.1002\/bjs.6135.","journal-title":"Br J Surg."},{"key":"19485_CR30","doi-asserted-by":"publisher","unstructured":"Fournier M, Huchon C, Ngo C, et al. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis. Eur J Surg Oncol. 2018;44(6):750-753. https:\/\/doi.org\/10.1016\/j.ejso.2018.01.005.","DOI":"10.1016\/j.ejso.2018.01.005"},{"issue":"9","key":"19485_CR31","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1097\/IGC.0000000000001369","volume":"28","author":"T Bartl","year":"2018","unstructured":"Bartl T, Schwameis R, Stift A, et al. Predictive and prognostic implication of bowel resections during primary cytoreductive surgery in advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2018;28(9):1664\u201371. https:\/\/doi.org\/10.1097\/IGC.0000000000001369.","journal-title":"Int J Gynecol Cancer."},{"issue":"2","key":"19485_CR32","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2019.30.e25","volume":"30","author":"R Tozzi","year":"2019","unstructured":"Tozzi R, Casarin J, Baysal A, et al. Bowel resection rate but not bowel related morbidity is decreased after interval debulking surgery compared to primary surgery in patents with stage IIIC-IV ovarian cancer. J Gynecol Oncol. 2019;30(2):e25. https:\/\/doi.org\/10.3802\/jgo.2019.30.e25.","journal-title":"J Gynecol Oncol."},{"issue":"1","key":"19485_CR33","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12893-022-01531-0","volume":"22","author":"S Ye","year":"2022","unstructured":"Ye S, Wang Y, Chen L, Wu X, Yang H, Xiang L. The surgical outcomes and perioperative complications of bowel resection as part of debulking surgery of advanced ovarian cancer patients. BMC Surg. 2022;22(1):81. https:\/\/doi.org\/10.1186\/s12893-022-01531-0.","journal-title":"BMC Surg."},{"issue":"11","key":"19485_CR34","doi-asserted-by":"publisher","first-page":"6922","DOI":"10.1097\/JS9.0000000000001474","volume":"110","author":"S Ni","year":"2024","unstructured":"Ni S, He J, Ouyang L. The value of transitory protective stomas during primary debulking surgery for advanced epithelial ovarian cancer: a retrospective cohort study. Int J Surg. 2024;110(11):6922\u201332. https:\/\/doi.org\/10.1097\/JS9.0000000000001474.","journal-title":"Int J Surg."},{"key":"19485_CR35","doi-asserted-by":"publisher","unstructured":"Trillsch F, Czogalla B, Mahner S, et al. Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3\/LION exploratory analysis. Int J Surg. 2025. https:\/\/doi.org\/10.1097\/JS9.0000000000002306.","DOI":"10.1097\/JS9.0000000000002306"},{"key":"19485_CR36","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-024-16731-6","author":"F Santullo","year":"2025","unstructured":"Santullo F, Vargiu V, Rosati A, et al. Risk factors for anastomotic leakage: a comprehensive single-center analysis of colorectal anastomoses for ovarian and gastrointestinal cancers. Ann Surg Oncol. 2025. https:\/\/doi.org\/10.1245\/s10434-024-16731-6.","journal-title":"Ann Surg Oncol."},{"key":"19485_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2021.100870","volume":"38","author":"B McNamara","year":"2021","unstructured":"McNamara B, Guerra R, Qin J, et al. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol Rep. 2021;38:100870. https:\/\/doi.org\/10.1016\/j.gore.2021.100870.","journal-title":"Gynecol Oncol Rep."},{"issue":"8","key":"19485_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/ijgc-2019-000682","volume":"29","author":"A Reuss","year":"2019","unstructured":"Reuss A, Du Bois A, Harter P, et al. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33\/AGO-OVAR OP7). Int J Gynecol Cancer. 2019;29(8):1327\u201331. https:\/\/doi.org\/10.1136\/ijgc-2019-000682.","journal-title":"Int J Gynecol Cancer."},{"key":"19485_CR39","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ijsu.2018.02.006","volume":"52","author":"J Zhou","year":"2018","unstructured":"Zhou J, Zhang W-W, Zhang Q-H, et al. The effect of lymphadenectomy in advanced ovarian cancer according to residual tumor status: a population-based study. Int J Surg. 2018;52:11\u20135. https:\/\/doi.org\/10.1016\/j.ijsu.2018.02.006.","journal-title":"Int J Surg."},{"issue":"7","key":"19485_CR40","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/ijgc-2024-005462","volume":"34","author":"Y Wang","year":"2024","unstructured":"Wang Y, Chen Y, Qin Z, Chen M, Zheng A, Han L. Splenectomy as a part of cytoreductive surgery in ovarian cancer: systematic review and meta-analysis. Int J Gynecol Cancer. 2024;34(7):1070\u20136. https:\/\/doi.org\/10.1136\/ijgc-2024-005462.","journal-title":"Int J Gynecol Cancer."},{"issue":"5","key":"19485_CR41","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1007\/s00404-021-06116-5","volume":"304","author":"MG Inci","year":"2021","unstructured":"Inci MG, Rasch J, Woopen H, Mueller K, Richter R, Sehouli J. ECOG and BMI as preoperative risk factors for severe postoperative complications in ovarian cancer patients: results of a prospective study (RISC-GYN-trial). Arch Gynecol Obstet. 2021;304(5):1323\u201333. https:\/\/doi.org\/10.1007\/s00404-021-06116-5.","journal-title":"Arch Gynecol Obstet."},{"issue":"9","key":"19485_CR42","doi-asserted-by":"publisher","first-page":"5630","DOI":"10.3390\/curroncol31090417","volume":"31","author":"J Heikkinen","year":"2024","unstructured":"Heikkinen J, K\u00e4rkk\u00e4inen H, Eloranta M-L, Anttila M. Postoperative complications of upfront ovarian cancer surgery and their effects on chemotherapy delay. Curr Oncol. 2024;31(9):5630\u201342. https:\/\/doi.org\/10.3390\/curroncol31090417.","journal-title":"Curr Oncol."},{"issue":"3","key":"19485_CR43","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.ygyno.2009.03.011","volume":"114","author":"CG Gerestein","year":"2009","unstructured":"Gerestein CG, Damhuis RAM, Burger CW, Kooi GS. Postoperative mortality after primary cytoreductive surgery for advanced stage epithelial ovarian cancer: a systematic review. Gynecol Oncol. 2009;114(3):523\u20137. https:\/\/doi.org\/10.1016\/j.ygyno.2009.03.011.","journal-title":"Gynecol Oncol."},{"issue":"7","key":"19485_CR44","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1001\/jamasurg.2019.0907","volume":"154","author":"A Melamed","year":"2019","unstructured":"Melamed A, Bercow AS, Bunnell K, et al. Age-associated risk of 90-day postoperative mortality after cytoreductive surgery for advanced ovarian cancer. JAMA Surg. 2019;154(7):669\u201371. https:\/\/doi.org\/10.1001\/jamasurg.2019.0907.","journal-title":"JAMA Surg."},{"key":"19485_CR45","doi-asserted-by":"publisher","unstructured":"Mahner S, Heitz F, Salehi S, et al. TRUST: Trial of radical upfront surgical therapy in advanced ovarian cancer (ENGOT ov33\/AGO\u2010OVAR OP7). J Clin Oncol. 2025;43(17_suppl). https:\/\/doi.org\/10.1200\/JCO.2025.43.17_suppl.LBA5500.","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA5500"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19485-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19485-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T04:02:20Z","timestamp":1780804940000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19485-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":45,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["19485"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19485-5","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,12]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The first author (IBR) is a founding member of the Ovarian Tumor Committee of the German Gynecologic Oncology Group (AGO) and a member of the author team releasing the \u201cS3 Guideline on Diagnosis, Treatment, and Follow-up of Malignant Ovarian Tumours.\u201d IBR is CEO and co-founder of RU21 GmbH (r-u-21.com), a company focused on longevity, prevention, and consumer healthcare. This role is independent of the research presented. The other authors declare no conflicts of interest. Institutional support; no external funding.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the ethics committee of the Jena University Hospital (no. 2021-2262-Daten on 09.06.2021)","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No identifying information is included in the manuscript. Analyses are exclusively based on data from clinical records, which in Germany are allowed to be used for research purposes by the attending clinic without explicit consent from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not commissioned, externally peer reviewed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}}]}}